Cell Therapeutics (CTIC)
Cell Therapeutics Free Cash Flow TTM: -57.41M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CTIC Free Cash Flow TTM Rankings
| Overall | 9th percentile | 3755 of 4138 |
| Sector | 9th percentile | 436 of 480 in Healthcare |
| Industry | 21st percentile | 117 of 149 in Biotechnology |
CTIC Free Cash Flow TTM Range, Past 5 Years
| Minimum | -110.58M | Sep 2007 |
| Maximum | -57.41M | Mar 2012 |
| Average | -82.55M |
About Free Cash Flow (TTM)
Free Cash Flow (TTM) is the sum of the last four quarters of Free Cash Flows.
For details about how YCharts calculates its quarterly Free Cash Flow numbers, click "Learn More" below.
Learn More
You may also be interested in these CTIC related companies
CTIC News
CellTherapeutics (CTIC) Gets Conditional EC Marketing Authorization for Pixuvri
May 11, 9:14AM Street Insider
May 11, 9:14AM Street Insider
Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Apr 20, 1:30AM PR Newswire
Apr 20, 1:30AM PR Newswire
Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Apr 19, 8:00PM PR Newswire
Apr 19, 8:00PM PR Newswire
Cell Therapeutics (CTIC) to Acquire Rights on S*BIO's Pacritinib JAK2 Inhibitor
Apr 19, 6:54AM Street Insider
Apr 19, 6:54AM Street Insider
Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET
Apr 18, 8:00PM PR Newswire
Apr 18, 8:00PM PR Newswire
Cell Therapeutics and Keryx Biopharmaceuticals Hope for Help From the TREAT Act
Mar 22, 8:20AM Marketwire
Mar 22, 8:20AM Marketwire
Cell Therapeutics and Avanir Pharmaceuticals Look to Make Headway in Strengthening Biotech Industry
Mar 12, 8:20AM Marketwire
Mar 12, 8:20AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CTIC | 0.91 | -0.01 | -1.09% | 206.22M |
| CTHR | 3.89 | +0.03 | +0.78% | 75.66M |
| CTGX | 12.45 | +0.16 | +1.30% | 230.70M |
| CTFO | 4.55 | -0.09 | -1.94% | 114.98M |
| CTEL | 10.58 | -0.19 | -1.76% | 408.92M |
| CTCT | 20.58 | +0.12 | +0.59% | 622.13M |
| CTCM | 9.35 | -0.10 | -1.06% | 1.471B |
| CTB | 15.21 | -0.25 | -1.62% | 947.58M |
| CTAS | 37.31 | -0.41 | -1.09% | 4.840B |
| CSU | 9.67 | +0.12 | +1.26% | 272.11M |
